Evidence map›Paper›PMID 39795613›Full record

ReviewDiagnostics (Basel, Switzerland)2025

DKK1 and Its Receptors in Esophageal Adenocarcinoma: A Promising Molecular Target.

Markos Despotidis, Orestis Lyros, Tatiana S Driva, Panagiotis Sarantis, Emmanouil I Kapetanakis, Adam Mylonakis, Andreas Mamilos, Stratigoula Sakellariou, Dimitrios Schizas

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Molecular Consequences ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Markos DespotidisFirst Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.ORCID 0000-0002-5836-7070
Orestis LyrosFourth Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0002-7727-7804
Tatiana S DrivaFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-9511-6393
Panagiotis SarantisDepartment of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-5848-7905
Emmanouil I KapetanakisDepartment of Thoracic Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0001-8354-4641
Adam MylonakisFirst Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.ORCID 0000-0002-0272-3259
Andreas MamilosInstitute of Pathology, University of Regensburg, 93053 Bavaria, Germany.
Stratigoula SakellariouFirst Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Dimitrios SchizasFirst Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.ORCID 0000-0002-7046-0112

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal adenocarcinoma (EAC) is an aggressive gastrointestinal (GI) malignancy with increasing incidence. Despite the recent progress in targeted therapies and surgical approaches, the survival rates of esophageal adenocarcinoma patients remain poor. The Dickkopf (DKK) proteins are secretory proteins known mainly as antagonists of the Wnt/β-catenin signaling pathway, which is considered an oncogene. However, it has been shown that in several GI cancers, including esophageal cancer, DKK1 may act as an oncogene itself through Wnt-independent signaling pathways. LRP5\6 and Kremen1/2 (Krm1/2) are transmembrane receptors to which the DKK proteins are mainly known to bind. CKAP4 (cytoskeleton-associated protein 4) is a novel receptor of DKK1, and the DKK1-CKAP4 pathway seems to be crucial in the role of DKK1 as an oncogene. The aim of this review is to feature the essential role of DKK1 and its receptors in carcinogenesis with a focus on EAC in an era of urgent need for specific biomarkers along with improved targeted therapies.

Indexed as

DKK proteinsDKK receptorsesophageal adenocarcinomamolecular targetWnt signaling pathway

Identifiers

PMID39795613
PMCPMC11720708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.